CKD and risk management : NICE guideline
|
|
- Ashley Hensley
- 5 years ago
- Views:
Transcription
1 CKD and risk management : NICE guideline Shahed Ahmed Consultant Nephrologist shahed.ahmed@rlbuht.nhs.uk
2 Key points : Changing parameters of CKD and NICE guidance CKD and age related change of GFR Nice guidance on lipid management with CKD CKD Vs AKI Community AKI project
3 Defining CKD CKD is present when either: The MDRD-derived estimated glomerular filtration rate (egfr) is less than 60ml/min on at least two occasions over a period of no less than 90 days Or, The urine ACR is >30mg/mmol (or, PCR is > 50mg/mmol)
4 Classification of CKD, based on NICE 2008 Stage of CKD Estimated GFR KIDNEY FUNCTION Stage 1 Stage 2 >90ml/min with urine abnormality or abnormal renal anatomy 60-89ml/min with urine abnormality or abnormal renal anatomy Normal Mild Reduced Stage 3a 45-59ml/min Mild to moderate reduced Stage 3b 30-44ml/min Moderate reduced Stage ml/min Severe reduced Stage 5 <15ml/min or dialysis dependant Kidney failure
5 Annual CVD Mortality (%) WHY CKD is a high risk disease? CV disease mortality : General Population vs. ESRD Dialysis Patients >85 Age (years) GP Male GP Female GP Black GP White Dialysis Male Dialysis Female Dialysis Black Dialysis White Foley RN, et al. Am J Kidney Dis. 1998;32:S112-S119.
6 Prevalence of Chronic Kidney Disease (CKD) Stages by Age Group in NHANES and
7 CV events N Engl J Med Sep 23;351(13): , Go et al, Kaiser Permanente Northern California
8 CKD- However, The majority of patients with CKD 1-3 do not progress to ESRF. Their risk of cardiovascular death is higher than their risk of progression.
9 Patients with CKD are more likely to die than go onto dialysis 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 9% 15% 25% 30% 40% Death ESRD/D Event Free No DM / CKD DM No CKD CKD No DM DM and CKD Dialysis Adapted from Collins, Adv Studies in Med, (3C) 2003, Medicare Cohort
10 In CKD early identification is essential! NICE: Chronic kidney disease Early identification and management of chronic kidney disease in adults in primary and secondary care Issue date: September 2008 The Challenges: However, because of a lack of specific symptoms, CKD are often not diagnosed, or diagnosed late. 30% of people with advanced CKD disease are referred late, causing increased mortality and morbidity.
11 CKD How we diagnose? Serum Cr Vs GFR
12 egfr: Practical Implementation Issues Apply only to age > 18 (MDRD ages: 18-70) Not Validated - AKI Transplant Pregnancy Ease of use. Good fit with data at lower GFR
13 Estimate GFR from Serum Creatinine:, AS. Levey, et al; Ann Intern Med. 1999;130: GFR = 170 x [Pcr] x [Age] x [0.762 female] x [1.180 black race] x [SUN] x [Alb] Modified Equation 7: GFR = 186 x [Pcr] x [Age] x [0.742 female] x [1.212 black race]
14 Age & GFR Functional changes Renal plasma flow 10%/decade Longitudinal study, mean reduction CCL 0.75ml/min/yr (92 out 0f 254 no reduction) Lindeman, R. D., Tobin, J., and Shock, N. W. (1985). Longitudinal studies on the rate of decline in renal function with age.journal of the American Geriatrics Society
15 NICE CKD 2008: Did we overkill CKD diagnosis? Group in NHANES and
16 WHATS NEW NICE CKD 2014 The new and updated areas include: Classification of CKD and identification of people at risk of CKD complications and progression The relationship between acute kidney injury and CKD Self-management of CKD Pharmacotherapy for CKD.
17 Classification of chronic kidney disease Classify CKD using a combination of GFR and ACR categories and be aware that: a. Increased ACR is associated with increased risk of progression b. Decreased GFR is associated with increased risk of progression c. Increased ACR and decreased GFR in combination multiply the risk of progression.
18
19 Identification and investigation of people who have or are at risk of developing CKD Consider using egfr cystatin C to confirm the diagnosis of CKD in people with :an egfr creatinine of ml/min/1.73 m2, sustained for at least 90 days and no proteinuria (albumin:creatinine ratio)acr less than 3mg/mmol)
20 CKD : aim of Rx CV risk reduction: Target BP control Rx of hyperlipidaemia Control of proteinuria Target primary disease: ex.- good control of diabetes Specific Rx for CKD
21 Adjusted relative risk of progression to CKD (95% CI) Blood pressure and progression of CKD patients with non-diabetic kidney disease Meta-analysis of 11 randomised controlled trials with or without ACEi MEDLINE Database < Systolic BP (mmhg) Jafar et al, Ann Intern Med 2003;139:
22
23 Blood pressure targets NICE CKD Guidance If CKD, blood pressure target: <140 mmhg SBP ( ) < 90 mmhg DBP (80-89) If diabetes and CKD or ACR 70 mg/mmol, blood pressure target: < 130 mmhg SBP < 80 mmhg DBP NICE Management of CKD: NICE 2008
24 NICE CKD 2014 Overview: management of CKD in primary care Identify those at risk by egfr and proteinuria measurement Explain to people they have the condition and encourage self-management Control blood pressure manage cardiovascular risk Medicine management
25 Cont.. Do not offer a combination of renin-angiotensin system antagonists to people with CKD And do not offer a renin-angiotensin system antagonist to people if pretreatment serum potassium is >5.0mmol/litre
26 Key priority: Promoting self-management of CKD BP control: Explain that reducing raised BP is a key factor in preventing the progression of CKD BP monitoring: Advise people to monitor their own BP at home Smoking cessation Blood sugar control (if they have diabetes) Diet: To avoid processed, high-salt and high-fat foods
27 Key priority: Assess & control cardio-vascular risk Statins: Use statins for primary prevention of cardiovascular disease in same way as in people without CKD Offer statins for secondary prevention of CVD irrespective of lipid values Offer antiplatelet drugs to people with CKD for the secondary prevention of CVD (but the risks of bleeding may be increased with multiple antiplatelet drugs)
28 NICE guideline: Lipid modification Feb 2014 prevention of CVD in primary care, use a systematic strategy to identify people aged who are likely to be at high risk Use the QRISK2 risk assessment tool to assess CVD risk for the primary prevention of CVD (more than 10%, 10 year CVD risk on assessment) Offer statin treatment for the primary prevention of CVD with atorvastatin 20 mg. Start statin treatment in people with established CVD, type 1 diabetes or type 2 diabetes with atorvastatin 80 mg.
29 NICE guideline: Lipid modification Feb In people with stage 1 or stage 2 CKD treat as primary prevention and initiate treatment with atorvastatin 20 mg if there is no evidence of CVD and more than 10% CVD risk on assessment with QRISK2. [new 2014] 64. In people with stage 1 or stage 2 CKD and evidence of CVD, start treatment with atorvastatin 20 mg and increase dose if a greater than 40% reduction in non-hdl cholesterol is not achieved. [new 2014] 65. In people with stage 3 CKD start high-intensity statin treatment with atorvastatin 20 mg. Increase the dose if a reduction in non-hdl cholesterol of greater than 40% is not achieved. [new 2014] 66. In people with CKD stage 4 or greater start treatment with atorvastatin 20 mg and agree the use of higher doses with a renal specialist. [new 2014]
30 Case 32 Year old lady, generally feeling unwell. H/O- HTN, depression On Lisinopril 20 mg, Furosemide 40 mg INV- S Cr 250/ egfr 29 Urine dip NAD BP, HR, RR normal limit Rx: 1. Urgent Renal O/P ref for CKD 4 2. Stop ACEI / repeat U&E, then consider referral 3. Urgent hospital Referral for AKI
31 AKI : Background Up to 18% of all hospital admissions have AKI Inpatient AKI-related mortality is between 25 and 30% Between 20 and 30% of cases of AKI are preventable. Prevention could save up to 12,000 lives each year NHS costs related to AKI are between 434 and 620 million per year
32 Cost of AKI 23 June 2011 Health Service Journal supplement 1
33 e-aki alert: Early Diagnosis of AKI
34 e-aki alert
35 Patient Details: Date: New Diagnosis of AKI (Stage 1 / Stage 2/ Stage 3) (Electronic AKI alert) Baseline Cr/ date: Latest Creatinine (Cr): Urine dip test: To arrange patient review (To exclude CKD) and medication review To repeat U & E within hours (i.e, as per AKI stages as below). AKI stage 1 AKI stage 2 AKI stage 3 -Treat underlying problems (dehydration, infection, medication review etc.) - Repeat U & Es in hours - Hospital admission if progressive /in appropriate cases 3 -Treat underlying problems (dehydration, infection, medication review etc.) - Consider Hospital admission in appropriate cases 3 ** - Repeat U & Es in 24 hours if treated in community 5 - Treat underlying probles (dehydration, sepsis, medication review etc.) -To arrange Hospital admission in appropriate cases 3 ** - Repeat U & Es 24 hours if treated in community 5 **Discuss with AKI team / on call renal Registrar if required and appropriate
36 Referral Nephrology: Discuss AKI management with a nephrologist/paediatric nephrologist as soon as possible (and within 24 hours) if one of the following is present: Potential diagnosis requiring specialist treatment (for example, vasculitis or glomerulonephritis) AKI with no clear cause Inadequate treatment response Complications associated with AKI Stage 3 AKI egfr is less than < 30 ml/min/1.73 m 2 after AKI episode Patients with renal transplant and AKI CKD stage 4 or 5 Renal replacement therapy: Refer adults, children and young people immediately for RRT if any of the following are not responding to medical management: Hyperkalaemia Metabolic acidosis Symptoms or complications of uraemia such as pericarditis or encephalopathy Fluid overload +/- pulmonary oedema
37 Summary 1: CKD - aim of Rx First, Identify CKD CV risk reduction: Target BP control / Rx of hyperlipidaemia Control of proteinuria ACEI/ARB Target primary disease: ex.- good control of diabetes Specific Rx for CKD anaemia / bone disease CKD vs. AKI
38 Thank you Any Question?
ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meeting 12 th September 2017 - Sheffield Prof Sunil Bhandari Consultant
More informationSwindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus
Swindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus 1 Contents Executive Summary... 3 How to Screen for Diabetic Nephropathy... 4 What to Measure... 4 Frequency
More informationThe National Quality Standards for Chronic Kidney Disease
The National Quality Standards for Chronic Kidney Disease Dr Robert Lewis Chief of Service, Wessex Kidney Centre, Portsmouth Specialist Committee Member Quality Standard for Chronic Kidney Disease, NICE
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationOffice Management of Reduced GFR Practical advice for the management of CKD
Office Management of Reduced GFR Practical advice for the management of CKD CKD Online Education CME for Primary Care April 27, 2016 Monica Beaulieu, MD FRCPC MHA CHAIR PROVINCIAL KIDNEY CARE COMMITTEE
More informationNephrology. 3 rd Year Revision Session 06/05/17 Cathal Hannan
Nephrology 3 rd Year Revision Session 06/05/17 Cathal Hannan Aims Acute Kidney Injury-recognition and management Sample OSCE Station Clinically relevant renal physiology Aetiology of Chronic Kidney Disease
More informationTREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009
TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meetings 1 st and 2 nd September 2016 - London and Leeds Prof Sunil
More informationThe role of the Nephrologist in Acute Kidney Injury. Rebecca Brown Consultant Nephrologist Royal Liverpool University Hospital
The role of the Nephrologist in Acute Kidney Injury Rebecca Brown Consultant Nephrologist Royal Liverpool University Hospital Overview Impact of AKI Need for change Who needs a Nephrologist Are we making
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationDoncaster & Bassetlaw. AKI guidelines for primary care
Doncaster & Bassetlaw AKI guidelines for primary care Contents: FLOW DIAGRAM: MANAGEMENT OF PATIENTS WITH AKI DETECTED IN PRIMARY CARE... 2 FLOW DIAGRAM: MANAGEMENT OF HYPERKALAEMIA.... 3 FLOW DIAGRAM:
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationBulletin Independent prescribing information for NHS Wales
Bulletin Independent prescribing information for NHS Wales October 2017 Chronic kidney disease Chronic kidney disease (CKD) is a long-term irreversible deterioration in the function of the kidneys, often
More informationChronic Kidney Disease. Paul Cockwell Queen Elizabeth Hospital Birmingham
Chronic Kidney Disease Paul Cockwell Queen Elizabeth Hospital Birmingham Paradigms for chronic disease 1. Acute and chronic disease is closely linked 2. Stratify risk and tailor interventions around failure
More informationNice CKD Clinical Guidelines 2014 The challenges and benefits they may bring toprimary care
Nice CKD Clinical Guidelines 2014 The challenges and benefits they may bring toprimary care Paula D Souza Senior CKD Nurse Specialist Royal Devon and Exeter Healthcare Trust Introduction Background What
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
More informationProfessor Suetonia Palmer
Professor Suetonia Palmer Department of Medicine Nephrologist Christchurch Hospital Christchurch 14:00-14:55 WS #108: The Kidney Test - When To Test and When to Refer ( and When Not To) 15:05-16:00 WS
More informationCKD at the primary and secondary care interface. Paul Cockwell Consultant Nephrologist Clinical Service Lead Renal Medicine, QEHB
CKD at the primary and secondary care interface Paul Cockwell Consultant Nephrologist Clinical Service Lead Renal Medicine, QEHB The Health improvement Network (THIN): 6.7 million patients from 426 primary
More information6/10/2014. Chronic Kidney Disease - General management and standard of care. Management of CKD according to stage (KDOQI 2002)
Chronic Kidney Disease - General management and standard of care Dr Nathalie Demoulin, Prof Michel Jadoul Cliniques universitaires Saint-Luc Université Catholique de Louvain What should and can be done
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationNORTHERN IRELAND GUIDELINES FOR MANAGEMENT OF CHRONIC KIDNEY DISEASE
NORTHERN IRELAND GUIDELINES FOR MANAGEMENT OF CHRONIC KIDNEY DISEASE Practical points for use of estimated GFR + quality outcome framework indicators Developed by GAIN and the Northern Ireland Nephrology
More informationACUTE KIDNEY INJURY FOCUS ON OBSTETRICS DONNA HIGGINS, CLINICAL NURSE EDUCATOR, NORTHERN LINCOLNSHIRE HOSPITALS NHS FOUNDATION TRUST
ACUTE KIDNEY INJURY FOCUS ON OBSTETRICS DONNA HIGGINS, CLINICAL NURSE EDUCATOR, NORTHERN LINCOLNSHIRE HOSPITALS NHS FOUNDATION TRUST AIMS & OBJECTIVES Review the functions of the kidney Identify renal
More informationAcute Kidney Injury (AKI) Undergraduate nurse education
Acute Kidney Injury (AKI) Undergraduate nurse education Year Three Developed Summer 2017 Objectives Understand Acute Kidney Injury and its relevance to patient care. Brief revision of the Anatomy and physiology
More informationLaunch Meeting 3 rd April 2014, Lucas House, Birmingham
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Launch Meeting 3 rd April 2014, Lucas House, Birmingham Prof Sunil Bhandari
More informationDisclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationDisclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationCKD & HT. Anne-Marie Angus
CKD & HT Anne-Marie Angus Hypertension definitions Persisting BP >140/90 and HBPM >135/85 Stage 1 >140/90 (HBPM >135/85) Stage 2 >160/100 (HBPM >150/90) Severe >180/100 White coat HT Why treat? A major
More informationConcept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA
Concept and General Objectives of the Conference: Prognosis Matters Andrew S. Levey, MD Tufts Medical Center Boston, MA General Objectives Topics to discuss What are the key outcomes of CKD? What progress
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationWEEK. MPharm Programme. Acute Kidney Injury. Alan M. Green MPHM13: Acute Kidney Injury. Slide 1 of 47
MPharm Programme Acute Kidney Injury Alan M. Green 2017 Slide 1 of 47 Overview Renal Function What is it? Why does it matter? What causes it? Who is at risk? What can we (Pharmacists) do? How do you recognise
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationIrish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012
Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Susan McKenna Renal Clinical Nurse Specialist Cavan General Hospital Renal patient population ACUTE RENAL FAILURE
More informationOutline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationClinical guideline Published: 23 July 2014 nice.org.uk/guidance/cg182
Chronic kidney disease in adults: assessment and management Clinical guideline Published: 23 July 2014 nice.org.uk/guidance/cg182 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationManaging Patients with CKD in Primary Care: A Shared Care Pathway. 5 th April 2018
Managing Patients with CKD in Primary Care: A Shared Care Pathway 5 th April 2018 Learning Objectives 1) What health risks does CKD represent? 2) Why change how we manage CKD in NWL? 1) How do we improve
More informationFaculty/Presenter Disclosure
CSI for CKD Unravelling the myths surrounding chronic kidney disease Practical Evidence for Informed Practice Oct 21 2016 Dr. Scott Klarenbach University of Alberta Slide 1: Option B (Presenter with NO
More informationLiverpool experience of Community AKI care
Liverpool experience of Community AKI care Shahed Ahmed Consultant Nephrologist and Honorary Lecturer Royal Liverpool University Hospital shahed.ahmed@rlbuht.nhs.uk Is AKI really a problem? 100000, deaths
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationChronic Kidney Disease
Chronic Kidney Disease Presence of kidney damage or decreased kidney function for three or more months, - necessary to distinguish CKD from acute kidney disease. Ascertained either by kidney biopsy or
More informationInterventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
More informationOutline. Introduction. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 6/26/2012
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationWhat should you do next? Presenter Disclosure Information. Learning Objectives. Case: George
2:45 3:45pm Optimizing the Management of Patients with Chronic Kidney Disease SPEAKER Jay B. Wish, MD, FACP Presenter Disclosure Information The following relationships exist related to this presentation:
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationChronic Kidney Disease (CKD) and egfr: Decision and Dilemma. Dr Bhavna K Pandya Consultant Nephrologist University Hospital Aintree
Chronic Kidney Disease (CKD) and egfr: Decision and Dilemma Dr Bhavna K Pandya Consultant Nephrologist University Hospital Aintree Topics CKD background egfr background Patient with egfr Referral Guidelines
More informationManagement of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA
Management of New-Onset Proteinuria in the Ambulatory Care Setting Akinlolu Ojo, MD, PhD, MBA Urine dipstick results Negative Trace between 15 and 30 mg/dl 1+ between 30 and 100 mg/dl 2+ between 100 and
More informationOptimal blood pressure targets in chronic kidney disease
Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management
More informationNational Audit of CKD in Primary Care
National Audit of CKD in Primary Care David C Wheeler Royal Free Campus University College London d.wheeler@ucl.ac.uk Kidney for General Physicians RCP London 24 th November 2017 Who looks after CKD patients
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationManaging Chronic Kidney Disease: Reducing Risk for CKD Progression
Managing Chronic Kidney Disease: Reducing Risk for CKD Progression Arasu Gopinath, MD Clinical Nephrologist, Medical Director, Jordan Landing Dialysis Center Objectives: Identify the most important risks
More informationSouthern Derbyshire Shared Care Pathology Guidelines. AKI guidelines for primary care
Southern Derbyshire Shared Care Pathology Guidelines AKI guidelines for primary care Contents: Flow Diagram: Recommended response time to AKI warning stage test results for adults in primary care 2 Table
More informationDiabetic Kidney Disease: Update. GKA Master Class. Istanbul 2011
Diabetic Kidney Disease: Update GKA Master Class Istanbul 2011 DKD: Challenging dogmas Old Dogmas Type 1 and Type 2 DN have the same natural history Microalbuminuria is an early stage of DN Tight Glycemia
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationFigure 1 LVH: Allowed Cost by Claim Volume (Data generated from a Populytics analysis).
Chronic Kidney Disease (CKD): The New Silent Killer Nelson Kopyt D.O. Chief of Nephrology, LVH Valley Kidney Specialists For the past several decades, the health care needs of Americans have shifted from
More informationAcknowledgements. National Kidney Foundation of Connecticut Mark Perazella. Co-PI Slowing the progression of chronic kidney disease to ESRD
A Practical Approach to Chronic Kidney Disease Management for the Primary Care Practioner: A web-site sponsored by the National Kidney Foundation of Connecticut Robert Reilly, M.D. Acknowledgements National
More informationEvaluation of Chronic Kidney Disease KDIGO. Paul E de Jong University Medical Center Groningen The Netherlands
Evaluation of Chronic Kidney Disease Paul E de Jong University Medical Center Groningen The Netherlands Evaluation and Management of CKD 1. Definition and classification of CKD 2. Definition and impact
More informationCHRONIC KIDNEY DISEASE DIAGNOSIS
CHRONIC KIDNEY DISEASE DIAGSIS GFR categories, description and range WHO SHOULD BE TESTED FOR CKD CLASSIFICATION OF CKD USING egfr AND ACR CATEGORIES Offer testing for CKD using egfr, creatinine and ACR
More informationDr A Pokrajac MD MSc MRCP Consultant
Dr A Pokrajac MD MSc MRCP Consultant Onset at 5-15 years of T1DM Can be present at diagnosis of T2DM Detect in regular MA/Cr screening (2X first urine sample, no UTI, no other causes) Contributing Factors
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table
More informationChronic Kidney Disease for the Primary Care Physician in What do the Kidneys do? CKD in the US
1:25-2:25pm Managing Chronic Kidney Disease in 2019 SPEAKERS Adriana Dejman, MD Chronic Kidney Disease for the Primary Care Physician in 2019 Adriana Dejman, MD Assistant Professor of Clinical Medicine
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationChronic kidney disease (CKD) (Southampton pathway)
Background information Patient information Key messages for this pathway Definitions and abbreviations used in this pathway Classification of CKD Diagnosis of CKD Summary of referral criteria Screening
More informationCKD and CVD. Jamal Salameh, MD, FACP, FASN First Coast Nephrology
CKD and CVD Jamal Salameh, MD, FACP, FASN First Coast Nephrology An Epidemic of Kidney Disease Prevalence CKD stages 1-4 10% 1988-94 13% 1999-2004 Coresh, JAMA 298:2038, 2007 Stage 5: GFR
More informationThe future is here. It s just not widely distributed yet. William Gibson
The future is here. It s just not widely distributed yet. William Gibson CHRONIC KIDNEY DISEASE MANAGEMENT A NEW PARADIGM Aaron Cass, MD, FRCPC Nephrologist, Fraser Health January 22, 2014 Where Are We
More informationElevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC
Elevation of Serum Creatinine: When to Screen, When to Refer Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC Presented at the University of Calgary s CME and Professional Development 2006-2007
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationIdentifying and Managing Chronic Kidney Disease: A Practical Approach
Identifying and Managing Chronic Kidney Disease: A Practical Approach S. Neil Finkle, MD, FRCPC Associate Professor Division of Nephrology, Department of Medicine, Dalhousie University Program Director,
More informationAdding Insult to Injury. Marlies Ostermann Consultant in Nephrology & Critical Care Guy s & St Thomas Hospital, London
Acute Kidney Injury Adding Insult to Injury Marlies Ostermann Consultant in Nephrology & Critical Care Guy s & St Thomas Hospital, London Content 1. Brief review of AKI and its impact 2. Comments on the
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease
More informationSession 9: Optimizing the Management of Patients with Chronic Kidney Disease Learning Objectives
Session 9: Optimizing the Management of Patients with Chronic Kidney Disease Learning Objectives 1. Understand the impact of chronic kidney disease (CKD) as a common condition of the adult US population.
More informationClinical Approach to the Patient At-Risk for Kidney Disease: Rationale for Testing for Serum Creatinine and Albuminuria
Clinical Approach to the Patient At-Risk for Kidney Disease: Rationale for Testing for Serum Creatinine and Albuminuria Allan J. Collins, MD, FACP Professor of Medicine University of Minnesota Director,
More informationChronic Kidney Disease: Optimal and Coordinated Management
Chronic Kidney Disease: Optimal and Coordinated Management Michael Copland, MD, FRCPC Presented at University of British Columbia s 42nd Annual Post Graduate Review in Family Medicine Conference, Vancouver,
More informationDialysis Initiation and Optimal Vascular Access: Outcomes and Mortality
Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality Shannon H. Norris, BSN, RN June 6, 2018 Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality DISCUSSION: End Stage
More informationCKDinform: A PCP s Guide to CKD Detection and Delaying Progression
CKDinform: A PCP s Guide to CKD Detection and Delaying Progression Learning Objectives Describe suitable screening tools, such as GFR and ACR, for proper utilization in clinical practice related to the
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationSERVICE SPECIFICATION 6 Conservative Management & End of Life Care
SERVICE SPECIFICATION 6 Conservative Management & End of Life Care Table of Contents Page 1 Key Messages 2 2 Introduction & Background 2 3 Relevant Guidelines & Standards 2 4 Scope of Service 3 5 Interdependencies
More informationScreening and early recognition of CKD. John Ngigi (FISN) Kidney specialist
Screening and early recognition of CKD John Ngigi (FISN) Kidney specialist screening Why? Who? When? How? Primary diagnosis for patients who start dialysis Other 10% Glomerulonephritis 13% No. of dialysis
More informationVA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERENCE CARDS Chronic Kidney Disease
VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERECE CARDS Chronic Kidney Disease CKD VA/DoD Clinical Practice Guideline for the Management
More informationCHRONIC KIDNEY DISEASE DIAGNOSIS
CHRONIC KIDNEY DISEASE DIAGSIS WHO SHOULD BE TESTED FOR CKD Offer testing for CKD using egfr, serum creatinine and urinary ACR to people with any of the following risk factors: diabetes hypertension acute
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationStatus of the CKD and ESRD treatment: Growth, Care, Disparities
Status of the CKD and ESRD treatment: Growth, Care, Disparities United States Renal Data System Coordinating Center An J. Collins, MD FACP Director USRDS Coordinating Center Robert Foley, MB Co-investigator
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationUric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George
Uric acid and CKD Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George Hospital @Badves Case Mr J, 52 Male, referred in June 2015 DM type 2 (4 years), HTN, diabetic retinopathy, diabetic
More informationChapter 2: Identification and Care of Patients With Chronic Kidney Disease
Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets
More informationCardiovascular Pharmacotherapy in Special Population: Cardio-Nephrology
49 th Annual Scientific Meeting The Heart Association of Thailand under the Royal Patronage of H.M. the King Cardiology on the move 24-25 March 2017 @Sheraton, HuaHin Cardiovascular Pharmacotherapy in
More informationRenal Replacement Therapy - Indication and Follow up
Renal Replacement Therapy - Indication and Follow up Prof Brigadier General Mamun Mostafi FCPS, FRCP Chief Physician Combined Military Hospital Dhaka Bangladesh Primary Functions of the Kidney Removal
More informationChronic Kidney Disease Management for Primary Care Physicians. Dr. Allen Liu Consultant Nephrologist KTPH 21 November 2015
Chronic Kidney Disease Management for Primary Care Physicians Dr. Allen Liu Consultant Nephrologist KTPH 21 November 2015 Singapore Renal Registry 2012 Incidence of Patients on Dialysis by Mode of Dialysis
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationPrevalence of anemia and cardiovascular diseases in chronic kidney disease patients: a single tertiary care centre study
International Journal of Advances in Medicine Sathyan S et al. Int J Adv Med. 2017 Feb;4(1):247-251 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20170120
More informationClassification of CKD by Diagnosis
Classification of CKD by Diagnosis Diabetic Kidney Disease Glomerular diseases (autoimmune diseases, systemic infections, drugs, neoplasia) Vascular diseases (renal artery disease, hypertension, microangiopathy)
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationCLINICAL GUIDELINE. Document No:CG38 *All Sites Management of adult patients referred to South Tees University Hospitals for hypertension.
GUIDELINE CLINICAL GUIDELINE Document No:CG38 *All Sites Management of adult patients referred to South Tees University Hospitals for hypertension. TITLE Management of adult patients referred to South
More information